Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 32513743
Kim E, et al. (2020) -GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity. Proc Natl Acad Sci U S A 117, 14259-14269 32513743
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T168-gl - LATS2 (human)
Modsite: GLMPTPVtRRPSFEG SwissProt Entrez-Gene
Orthologous residues
LATS2 (human): T168‑gl, LATS2 (mouse): T167‑gl, LATS2 (rat): T168‑gl
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
O-GlcNAc TRANSFERASE OGT (human) siRNA inhibition of enzyme, transfection of wild-type enzyme, pharmacological activator of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease OGT-siRNA decreases GlcNAcylation
thiamet-G increase
Downstream Regulation
Effect of modification (function):  phosphorylation
Effect of modification (process):  carcinogenesis, induced, cell growth, induced
Comments:  inhibits phosphorylation at LATS2-S872 and T1041

T436-gl - LATS2 (human)
Modsite: PNTVTAVtAAHILHP SwissProt Entrez-Gene
Orthologous residues
LATS2 (human): T436‑gl, LATS2 (mouse): T406‑gl, LATS2 (rat): T405‑gl
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
O-GlcNAc TRANSFERASE OGT (human) siRNA inhibition of enzyme, transfection of wild-type enzyme, pharmacological activator of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease OGT-siRNA decreases GlcNAcylation
thiamet-G increase
Downstream Regulation
Effect of modification (function):  activity, inhibited, molecular association, regulation, phosphorylation
Effect of modification (process):  carcinogenesis, induced, cell growth, induced, signaling pathway regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
MOB1B (human) Disrupts co-immunoprecipitation
Comments:  inhibits phosphorylation at LATS2-S872 and T1041, inturrupts hippo-pathway

S872-p - LATS2 (human)
Modsite: HQRCLAHsLVGTPNY SwissProt Entrez-Gene
Orthologous residues
LATS2 (human): S872‑p, LATS2 (mouse): S830‑p, LATS2 (rat): S830‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE MST1 (human) phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
OGT (human) decrease siRNA increases

T1041-p - LATS2 (human)
Modsite: EHAFYEFtFRRFFDD SwissProt Entrez-Gene
Orthologous residues
LATS2 (human): T1041‑p, LATS2 (mouse): T999‑p, LATS2 (rat): T999‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE MST1 (human) phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
OGT (human) decrease siRNA increases

S89-p - TAZ (human)
Modsite: AQHVRSHsSPASLQL SwissProt Entrez-Gene
Orthologous residues
TAZ (human): S89‑p, TAZ (mouse): S89‑p, TAZ (rat): S89‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE LATS2 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme, inhibition of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
OGT (human) decrease siRNA increases
mutation increase LATS-T436A and T168A mutant

S109-p - YAP1 (human)
Modsite: KSHSRQAsTDAGTAG SwissProt Entrez-Gene
Orthologous residues
YAP1 (human): S109‑p, YAP1 iso2 (human): S109‑p, YAP1 iso3 (human): S109‑p, YAP1 iso5 (human): S109‑p, YAP1 iso6 (human): S109‑p, YAP1 iso7 (human): S109‑p, YAP1 iso8 (human): S109‑p, YAP1 iso9 (human): S109‑p, YAP1 (mouse): S94‑p, YAP1 (rat): S94‑p, YAP1 iso3 (rat): S94‑p, YAP1 (sheep): S24‑p, YAP1 (cow): S37‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE LATS2 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme, inhibition of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
OGT (human) decrease siRNA increases
mutation increase LATS-T436A and T168A mutant

S127-p - YAP1 (human)
Modsite: PQHVRAHsSPASLQL SwissProt Entrez-Gene
Orthologous residues
YAP1 (human): S127‑p, YAP1 iso2 (human): S127‑p, YAP1 iso3 (human): S127‑p, YAP1 iso5 (human): S127‑p, YAP1 iso6 (human): S127‑p, YAP1 iso7 (human): S127‑p, YAP1 iso8 (human): S127‑p, YAP1 iso9 (human): S127‑p, YAP1 (mouse): S112‑p, YAP1 (rat): S112‑p, YAP1 iso3 (rat): S112‑p, YAP1 (sheep): S42‑p, YAP1 (cow): S55‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE LATS2 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme, inhibition of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
OGT (human) decrease siRNA increases
siRNA decrease LATS2-siRNA decreases phosphorylation
mutation increase LATS-T436A and T168A mutant